Stent-based antirestenotic coatings (sirolimus/paclitaxel).
Oberhoff
Martin
M
Bristol Heart Institute, University of Bristol, Bristol, U.K. martin.oberhoff@bristol.ac.uk
Herdeg
Christian
C
Baumbach
Andreas
A
Karsch
Karl R
KR
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects; D002986:Clinical Trials as Topic; D020099:Coated Materials, Biocompatible; D023903:Coronary Restenosis / Q000209:etiology / Q000517:prevention & control*; D003864:Depression, Chemical; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000494:pharmacology; D015918:Infusion Pumps, Implantable; D009131:Muscle, Smooth, Vascular / Q000166:cytology; D017239:Paclitaxel / Q000008:administration & dosage* / Q000494:pharmacology; D020123:Sirolimus / Q000008:administration & dosage* / Q000494:pharmacology; D015607:Stents / Q000009:adverse effects
D000972:Antineoplastic Agents, Phytogenic; D020099:Coated Materials, Biocompatible; D007166:Immunosuppressive Agents; D017239:Paclitaxel; D020123:Sirolimus